Arrhythmias & electrophysiology
International Multicenter Cohort Study on Beta-Blocker–Free Treatment Strategies for Catecholaminergic Polymorphic Ventricular Tachycardia Patients
Authors' conclusion
Although nonselective BBs remain the cornerstone treatment for CPVT, 10% of patients with CPVT required a BB-free treatment strategy. After careful risk assessment, safe and effective BB-free treatment strategies can be configured.
Study context
- Population
- Patients with RYR2 variant-positive catecholaminergic polymorphic ventricular tachycardia (CPVT) in the International CPVT Registry treated with a BB-free strategy for ≥6 monthsof 1,017 registry patients
- Participants
- 100 patients
- Exposure
- BB-free treatment strategies: intentional nontherapy vs non-BB treatment in BB-intolerant patients
- Intentional nontherapy (INT)n = 73
- BB-free treatmentn = 27
- Outcome
- CPVT-associated event
- Follow-up
- Median 6 years (IQR: 3-9 years)
Methodological detailsinternational, multicentre, registry-based
- International
- Multicentre
- Registry-based
Main finding
As reported in the abstract
Patients with a CPVT-associated event (overall)
2
2%
Observational data: associations, not effects.
Further findings
- INT pursued after low-risk assessment (asymptomatic, absent or negligible stress test phenotype)
- 90% · 66 of 73
BB-free treatment strategies used
- Flecainide monotherapy
- 21
- Left cardiac sympathetic denervation monotherapy
- 2
- Flecainide + left cardiac sympathetic denervation
- 4
Previously treated with beta-blockers (BBs)
- Patients previously treated with BBs
- 25 (93%)
Original publication
International Multicenter Cohort Study on Beta-Blocker–Free Treatment Strategies for Catecholaminergic Polymorphic Ventricular Tachycardia Patients. JACC Clin Electrophysiol. Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →